Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Ghatage, Prafull
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer	Recruiting	3	418	Europe, Canada, US, RoW	Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab	ImmunoGen, Inc., GOG Foundation	Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer	03/27	04/29
NCT03480776: ASA in Prevention of Ovarian Cancer (STICs and STONEs)	Active, not recruiting	2	117	Canada, RoW	Acetylsalicylic acid, ASA, Placebo	Canadian Cancer Trials Group, Apotex Inc.	Ovarian Cancer Prevention	12/24	09/25
GARNET, NCT02715284: Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022 Sep 2022 - Sep 2022: Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022 Data from the GARNET study in solid tumor at ASCO GI 2020 Jan 2021 - Jan 2021: Data from the GARNET study in solid tumor at ASCO GI 2020 Data from the GARNET study in recurrent or advanced endometrial cancer at ESMO 2020 Sep 2020 - Sep 2020: Data from the GARNET study in recurrent or advanced endometrial cancer at ESMO 2020 Data from the GARNET study in recurrent or advanced endometrial cancer Apr 2020 - Apr 2020: Data from the GARNET study in recurrent or advanced endometrial cancer Additional data from GARNET trial for advanced solid tumors Nov 2019 - Nov 2019: Additional data from GARNET trial for advanced solid tumors From GARNET trial for 2L recurrent/advanced endometrial cancer Mar 2019 - Mar 2019: From GARNET trial for 2L recurrent/advanced endometrial cancer From GARNET trial at SITC 2018 [screenshot] Nov 2018 - Nov 2018: From GARNET trial at SITC 2018 [screenshot] Additional data from GARNET trial in advanced solid tumors at SITC 2018 Nov 2018 - Nov 2018: Additional data from GARNET trial in advanced solid tumors at SITC 2018 From GARNET trial at ESMO 2018 [screenshot] Oct 2018 - Oct 2018: From GARNET trial at ESMO 2018 [screenshot] Updated data for rec or adv MSI-H endometrial cancer [GARNET] Oct 2018 - Oct 2018: Updated data for rec or adv MSI-H endometrial cancer [GARNET] From GARNET trial at AACR 2018 [screenshot] Apr 2018 - Apr 2018: From GARNET trial at AACR 2018 [screenshot] Summarized initial results Apr 2018 - Apr 2018: Summarized initial results Summarized initial results Apr 2018 - Apr 2018: Summarized initial results In solid tumors at ASCO 2017 Jun 2017 - Jun 2017: In solid tumors at ASCO 2017 More	Recruiting	1	740	Europe, Canada, US, RoW	Dostarlimab	Tesaro, Inc.	Neoplasms	05/26	10/27
Curman, Darko
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer	Recruiting	3	418	Europe, Canada, US, RoW	Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab	ImmunoGen, Inc., GOG Foundation	Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer	03/27	04/29